Cognition Therapeutics Stock Price, News & Analysis (NASDAQ:CGTX) $1.31 -0.06 (-4.38%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$1.26▼$1.4150-Day Range$0.96▼$1.4452-Week Range$0.90▼$3.49Volume40,250 shsAverage Volume100,464 shsMarket Capitalization$39.85 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cognition Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside358.0% Upside$6.00 Price TargetShort InterestHealthy1.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.93) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector257th out of 948 stocksBiological Products, Except Diagnostic Industry33rd out of 148 stocks 3.5 Analyst's Opinion Consensus RatingCognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Cognition Therapeutics has a forecasted upside of 358.0% from its current price of $1.31.Amount of Analyst CoverageCognition Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.10% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 19.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGTX. Previous Next 2.2 News and Social Media Coverage News SentimentCognition Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cognition Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.80% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.43% of the stock of Cognition Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cognition Therapeutics are expected to decrease in the coming year, from ($0.93) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cognition Therapeutics Stock (NASDAQ:CGTX)Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.Read More CGTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGTX Stock News HeadlinesDecember 4, 2023 | americanbankingnews.comCritical Review: Cognition Therapeutics (NASDAQ:CGTX) vs. Invivyd (NASDAQ:IVVD)November 22, 2023 | morningstar.comCognition Therapeutics Inc CGTXDecember 5, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. November 16, 2023 | finance.yahoo.comCognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensNovember 15, 2023 | stockhouse.comCognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's DiseasesNovember 15, 2023 | finance.yahoo.comCognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s DiseasesNovember 7, 2023 | benzinga.comCognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseNovember 7, 2023 | finance.yahoo.comCognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseDecember 5, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. November 3, 2023 | finance.yahoo.comCognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial ResultsNovember 2, 2023 | msn.comCognition Therapeutics GAAP EPS of $0.22 beats by $0.46November 2, 2023 | finance.yahoo.comCognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 27, 2023 | finance.yahoo.comCognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTADOctober 24, 2023 | stockhouse.comCognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTADOctober 24, 2023 | finance.yahoo.comCognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTADOctober 16, 2023 | finance.yahoo.comCognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS IndicationsSeptember 27, 2023 | thestreet.comCognition Therapeutics Inc.September 7, 2023 | finance.yahoo.comCognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMDAugust 30, 2023 | finance.yahoo.comCognition Therapeutics Announces Participation in Upcoming September ConferencesAugust 14, 2023 | msn.comLadenburg Thalmann Maintains Cognition Therapeutics (CGTX) Buy RecommendationAugust 9, 2023 | finance.yahoo.comWill Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely?August 9, 2023 | finance.yahoo.comQ2 2023 Cognition Therapeutics Inc Earnings CallAugust 8, 2023 | finanznachrichten.deCognition Therapeutics, Inc.: Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateAugust 8, 2023 | finance.yahoo.comCognition Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateAugust 8, 2023 | benzinga.comCognition Therapeutics's Earnings OutlookAugust 8, 2023 | finance.yahoo.comCognition Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateAugust 2, 2023 | finance.yahoo.comCognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023See More Headlines Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGTX CUSIPN/A CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+358.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.53% Return on Assets-51.07% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.39 per share Price / Book0.94Miscellaneous Outstanding Shares30,420,000Free Float23,178,000Market Cap$39.85 million OptionableNot Optionable Beta1.36 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Lisa Ricciardi (Age 63)CEO, President & Director Comp: $794.04kDr. Anthony O. Caggiano M.D.Ph.D., Chief Medical Officer and Head of R&DMr. John Brendan Doyle (Age 46)Chief Financial Officer Dr. Steven A. Weissman Ph.D.VP & Head of CMCKey CompetitorsCyclo TherapeuticsNASDAQ:CYTHElutiaNASDAQ:ELUTMiNK TherapeuticsNASDAQ:INKTAchilles TherapeuticsNASDAQ:ACHLFreeline TherapeuticsNASDAQ:FRLNView All CompetitorsInstitutional OwnershipSteward Financial Group LLCBought 40,874 shares on 10/23/2023Ownership: 0.135%View All Institutional Transactions CGTX Stock Analysis - Frequently Asked Questions Should I buy or sell Cognition Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGTX shares. View CGTX analyst ratings or view top-rated stocks. What is Cognition Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 1-year price targets for Cognition Therapeutics' shares. Their CGTX share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 358.0% from the stock's current price. View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts. How have CGTX shares performed in 2023? Cognition Therapeutics' stock was trading at $2.10 at the beginning of 2023. Since then, CGTX stock has decreased by 37.6% and is now trading at $1.31. View the best growth stocks for 2023 here. Are investors shorting Cognition Therapeutics? Cognition Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 240,200 shares, a drop of 19.1% from the October 31st total of 296,800 shares. Based on an average trading volume of 98,900 shares, the short-interest ratio is currently 2.4 days. Currently, 1.1% of the shares of the company are sold short. View Cognition Therapeutics' Short Interest. When is Cognition Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our CGTX earnings forecast. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.09. When did Cognition Therapeutics IPO? (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share. Who are Cognition Therapeutics' major shareholders? Cognition Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Steward Financial Group LLC (0.13%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace. View institutional ownership trends. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CGTX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.